Project Grant W81XWH0810260

This Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is supporting research to understand tumorigenesis and identify therapeutic targets in CDK12-mutant prostate cancer. The $1,944,610 award, which began on April 1, 2025 and will run through March 31, 2028, was granted to the Sloan-Kettering Institute for Cancer Research, a leading nonprofit cancer research institution in New York. The research involves a...

Federal Grant Award Summary The National Cancer Institute awarded a $410,933 Project Grant (CFDA 93.395 – Cancer Treatment Research) to the University of California, San Diego on March 18, 2026, with completion targeted for February 29, 2028. This exploratory research grant (R21 mechanism) supports the development of next-generation small interfering RNA (siRNA) therapeutics designed to enhance delivery of siRNA molecules into metastatic castration-resistant prostate cancer (MCRPC) tumor cells...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...

This $1,261,143 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Indiana University to exploit metabolic reprogramming of prostate cancer for new therapeutics. The key research tasks include: Determining the mechanism of p53 expression activation following loss of GCN2 in prostate cancer cell lines. Evaluating the effects on gene expression and metabolism when p53 is lost in GCN2-inhibited prostate...

Federal Cooperative Agreement Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $225,511 Cooperative Agreement award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective March 16, 2026, with a completion date of February 29, 2028. The award supports the development and validation of a plasma-based multimodal digital polymerase chain reaction (PCR) assay to detect androgen receptor (AR) somatic...

Purdue University will use a $465,000 Project Grant award from the Department of the Army Medical Command to support research titled "LIGAND-TARGETED MIRNA DELIVERY FOR PROSTATE CANCER THERAPY" from March 2021 to February 2023. The award is funded through the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research solutions for battlefield medicine and other health issues....

The Sloan-Kettering Institute for Cancer Research was awarded a $1,327,473 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research efforts from June 2021 through May 2024 to develop strategies for overcoming prostate stromal-derived neuregulin 1-mediated resistance to androgen receptor blockade in high-risk locally advanced prostate cancer. The Military Medical Research and...

The U.S. Department of Defense's Defense Health Agency awarded a $526,042 Project Grant to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, to support research aimed at identifying and targeting mechanisms of prostate cancer therapy resistance driven by the tumor microenvironment. The project will be conducted over a 2-year period from May 1, 2024 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). This research grant...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a Project Grant of $658,492 under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a novel targeted combinatorial therapy for advanced castration-resistant prostate cancer (ACRPC). The research, spanning from March 18, 2026 through February 28, 2031, focuses on optimizing the combination of CHK1 inhibitor SRA737 and WEE1 inhibitor AZD1775 to exploit the G2/M...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $433,157 to the Northshore University Healthsystem Research Institute to investigate the role of lipid-rich macrophages in the tumor microenvironment of prostate cancer. The primary objectives are to define the mechanisms regulating the immuno-metabolic axis in adipose tissue macrophages and tumor-associated macrophages, and determine whether a metabolically-activated macrophage...